Publikationen, an denen er mitarbeitet ANGELA PEÑALVA MAQUEDA (22)

2002

  1. Presence of bovine leptin in edible commercial milk and infant formula

    Journal of Endocrinological Investigation, Vol. 25, Núm. 8, pp. 670-674

2001

  1. Effect of acute pharmacological modulation of plasma free fatty acids on GH secretion in acromegalic patients

    Clinical Endocrinology, Vol. 54, Núm. 4, pp. 509-513

  2. Involvement of nitric oxide in the regulation of growth hormone secretion in dogs

    Neuroendocrinology, Vol. 74, Núm. 4, pp. 213-219

  3. Physiology and possible pathology of growth hormone secretagogues

    Journal of Pediatric Endocrinology and Metabolism, Vol. 14, Núm. SUPPL. 5, pp. 1207-1212

1998

  1. Acute changes in free-fatty acids (FFA) do not alter serum leptin levels

    Journal of Endocrinological Investigation, Vol. 21, Núm. 8, pp. 526-530

  2. Effect of acute pharmacological reduction of plasma free fatty acids on growth hormone (GH) releasing hormone-induced GH secretion in obese adults with and without hypopituitarism

    Journal of Clinical Endocrinology and Metabolism, Vol. 83, Núm. 12, pp. 4350-4354

  3. La administracion por via oral de dosis bajas de growth hormone releasing hexapeptide-6-mas piridostigmina es un estimulo adecuado de la secrecion de GH

    Endocrinologia, Vol. 45, Núm. 10, pp. 341-344

1996

  1. Acipimox-mediated plasma free fatty acid depression per se stimulates growth hormone (GH) secretion in normal subjects and potentiates the response to other GH-releasing stimuli

    Journal of Clinical Endocrinology and Metabolism, Vol. 81, Núm. 3, pp. 909-913

  2. Growth hormone releasing hexapeptide-6 (GHRP-6) in test in the diagnosis of GH-deficiency

    Journal of Pediatric Endocrinology and Metabolism

  3. Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression

    Journal of Clinical Endocrinology and Metabolism, Vol. 81, Núm. 3, pp. 914-918

1995

  1. Absence of growth hormone (GH) secretion after the administration of either GH-releasing hormone (GHRH), GH-releasing peptide (GHRP-6), or GHRH plus GHRP-6 in children with neonatal pituitary stalk transection

    Journal of Clinical Endocrinology and Metabolism, Vol. 80, Núm. 11, pp. 3180-3184

  2. Effect of combined administration of growth hormone (GH)-releasing hormone, GH-releasing peptide-6, and pyridostigmine in normal and obese subjects

    Metabolism, Vol. 44, Núm. 6, pp. 745-748

  3. Plasma growth hormone response to growth hormone‐releasing hexapeptide (GH‐RP‐6) in children with short stature

    Acta Pædiatrica, Vol. 84, Núm. 8, pp. 904-908

1994

  1. CONTROL PEPTIDERGICO DE LA SECRECION DE HORMONA DE CRECIMIENTO

    Endocrinologia, Vol. 41, Núm. SUPPL. 2, pp. 9-16

1993

  1. Effect of growth hormone (GH)-releasing hormone (GHRH), atropine, pyridostigmine, or hypoglycemia on GHRP-6-induced GH secretion in man

    Journal of Clinical Endocrinology and Metabolism, Vol. 76, Núm. 1, pp. 168-171

  2. Influence of sex, age and adrenergic pathways on the growth hormone response to GHRP-6

    Clinical Endocrinology, Vol. 38, Núm. 1, pp. 87-91

  3. Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: Evidence for a marked somatotroph secretory capability in obesity

    Journal of Clinical Endocrinology and Metabolism, Vol. 76, Núm. 4, pp. 819-823

1990

  1. Dual and selective actions of glucocorticoids upon basal and stimulated growth hormone release in man

    Neuroendocrinology, Vol. 51, Núm. 1, pp. 51-58

  2. Effect of enhancement of endogenous cholinergic tone with pyridostigmine on the dose-response relationships of growth hormone (GH)-releasing hormone-induced GH secretion in normal subjects

    Journal of Clinical Endocrinology and Metabolism, Vol. 70, Núm. 2, pp. 324-327

  3. ROLE OF CHOLINERGIC MUSCARINIC PATHWAYS ON THE FREE FATTY ACID INHIBITION OF GH RESPONSES TO GHRH IN NORMAL MEN

    Clinical Endocrinology, Vol. 33, Núm. 2, pp. 171-176